http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 08:00:53 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/CEL-SCI+to+sign+Saudi+Arabia+distribution+deal+for+Multikine+at+BIO+2026/26638397.html <p>CEL-SCI Corporation (NYSE American: CVM) will participate in a signing ceremony with Saudi Amarox during the BIO International Convention 2026 in San Diego to formalize their strategic agreement for commercializing Multikine in Saudi Arabia.</p> <p>The ceremony is scheduled for June 22, 2026, from 12:00 PM to 1:00 PM PST at the Saudi Amarox booth during the convention's opening ceremony. CEL-SCI Chief Executive Officer Geert Kersten and Amarox representatives will attend the event.</p> <p>Under the previously announced agreement, the companies will share revenue equally from Multikine sales in Saudi Arabia upon receiving Breakthrough Medicine Designation. Amarox will serve as the local regulatory representative http://www.streetinsider.com/Corporate+News/CEL-SCI+to+sign+Saudi+Arabia+distribution+deal+for+Multikine+at+BIO+2026/26638397.html Fri, 12 Jun 2026 08:00:53 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Corporate+News/CEL-SCI+to+sign+Saudi+Arabia+distribution+deal+for+Multikine+at+BIO+2026/26638397.html <p>CEL-SCI Corporation (NYSE American: CVM) will participate in a signing ceremony with Saudi Amarox during the BIO International Convention 2026 in San Diego to formalize their strategic agreement for commercializing Multikine in Saudi Arabia.</p> <p>The ceremony is scheduled for June 22, 2026, from 12:00 PM to 1:00 PM PST at the Saudi Amarox booth during the convention's opening ceremony. CEL-SCI Chief Executive Officer Geert Kersten and Amarox representatives will attend the event.</p> <p>Under the previously announced agreement, the companies will share revenue equally from Multikine sales in Saudi Arabia upon receiving Breakthrough Medicine Designation. Amarox will serve as the local regulatory representative http://www.streetinsider.com/Corporate+News/CEL-SCI+to+sign+Saudi+Arabia+distribution+deal+for+Multikine+at+BIO+2026/26638397.html Fri, 12 Jun 2026 08:00:53 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Corporate+News/CEL-SCI+to+sign+Saudi+Arabia+distribution+deal+for+Multikine+at+BIO+2026/26638397.html <p>CEL-SCI Corporation (NYSE American: CVM) will participate in a signing ceremony with Saudi Amarox during the BIO International Convention 2026 in San Diego to formalize their strategic agreement for commercializing Multikine in Saudi Arabia.</p> <p>The ceremony is scheduled for June 22, 2026, from 12:00 PM to 1:00 PM PST at the Saudi Amarox booth during the convention's opening ceremony. CEL-SCI Chief Executive Officer Geert Kersten and Amarox representatives will attend the event.</p> <p>Under the previously announced agreement, the companies will share revenue equally from Multikine sales in Saudi Arabia upon receiving Breakthrough Medicine Designation. Amarox will serve as the local regulatory representative http://www.streetinsider.com/Corporate+News/CEL-SCI+to+sign+Saudi+Arabia+distribution+deal+for+Multikine+at+BIO+2026/26638397.html Fri, 12 Jun 2026 08:00:53 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Corporate+News/CEL-SCI+to+sign+Saudi+Arabia+distribution+deal+for+Multikine+at+BIO+2026/26638397.html <p>CEL-SCI Corporation (NYSE American: CVM) will participate in a signing ceremony with Saudi Amarox during the BIO International Convention 2026 in San Diego to formalize their strategic agreement for commercializing Multikine in Saudi Arabia.</p> <p>The ceremony is scheduled for June 22, 2026, from 12:00 PM to 1:00 PM PST at the Saudi Amarox booth during the convention's opening ceremony. CEL-SCI Chief Executive Officer Geert Kersten and Amarox representatives will attend the event.</p> <p>Under the previously announced agreement, the companies will share revenue equally from Multikine sales in Saudi Arabia upon receiving Breakthrough Medicine Designation. Amarox will serve as the local regulatory representative http://www.streetinsider.com/Corporate+News/CEL-SCI+to+sign+Saudi+Arabia+distribution+deal+for+Multikine+at+BIO+2026/26638397.html Fri, 12 Jun 2026 08:00:53 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Press+Releases/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html <p class="bwalignc"> <i>Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030</i> </p><p class="bwalignc"> <i>Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies</i> </p><p class="bwalignc"> <i>Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets</i> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=9bc30e290eb6076fd78c45b399fd2429" shape="rect">CEL-SCI Corporation </a><b>(NYSE American: CVM) </b>today announced it will participate in a formal signing ceremony with Saudi Amarox ("<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsaudiamarox.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=Amarox&amp;index=2&amp;md5=71f13611ea7c0e8f95d5b86a9c320a8e" shape="rect">Amarox</a>") during the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconvention.bio.org%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=BIO+International+Convention&amp;index=3&amp;md5=c6c8b957173e61a9a05dae92bd9e3b86" shape="rect">BIO International Convention</a> 2026 in San Diego, California. The ceremony will mark an important http://www.streetinsider.com/Press+Releases/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html Fri, 12 Jun 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Press+Releases/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html <p class="bwalignc"> <i>Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030</i> </p><p class="bwalignc"> <i>Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies</i> </p><p class="bwalignc"> <i>Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets</i> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=9bc30e290eb6076fd78c45b399fd2429" shape="rect">CEL-SCI Corporation </a><b>(NYSE American: CVM) </b>today announced it will participate in a formal signing ceremony with Saudi Amarox ("<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsaudiamarox.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=Amarox&amp;index=2&amp;md5=71f13611ea7c0e8f95d5b86a9c320a8e" shape="rect">Amarox</a>") during the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconvention.bio.org%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=BIO+International+Convention&amp;index=3&amp;md5=c6c8b957173e61a9a05dae92bd9e3b86" shape="rect">BIO International Convention</a> 2026 in San Diego, California. The ceremony will mark an important http://www.streetinsider.com/Press+Releases/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html Fri, 12 Jun 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Press+Releases/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html <p class="bwalignc"> <i>Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030</i> </p><p class="bwalignc"> <i>Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies</i> </p><p class="bwalignc"> <i>Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets</i> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=9bc30e290eb6076fd78c45b399fd2429" shape="rect">CEL-SCI Corporation </a><b>(NYSE American: CVM) </b>today announced it will participate in a formal signing ceremony with Saudi Amarox ("<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsaudiamarox.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=Amarox&amp;index=2&amp;md5=71f13611ea7c0e8f95d5b86a9c320a8e" shape="rect">Amarox</a>") during the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconvention.bio.org%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=BIO+International+Convention&amp;index=3&amp;md5=c6c8b957173e61a9a05dae92bd9e3b86" shape="rect">BIO International Convention</a> 2026 in San Diego, California. The ceremony will mark an important http://www.streetinsider.com/Press+Releases/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html Fri, 12 Jun 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Press+Releases/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html <p class="bwalignc"> <i>Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030</i> </p><p class="bwalignc"> <i>Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies</i> </p><p class="bwalignc"> <i>Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets</i> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=9bc30e290eb6076fd78c45b399fd2429" shape="rect">CEL-SCI Corporation </a><b>(NYSE American: CVM) </b>today announced it will participate in a formal signing ceremony with Saudi Amarox ("<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsaudiamarox.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=Amarox&amp;index=2&amp;md5=71f13611ea7c0e8f95d5b86a9c320a8e" shape="rect">Amarox</a>") during the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconvention.bio.org%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=BIO+International+Convention&amp;index=3&amp;md5=c6c8b957173e61a9a05dae92bd9e3b86" shape="rect">BIO International Convention</a> 2026 in San Diego, California. The ceremony will mark an important http://www.streetinsider.com/Press+Releases/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html Fri, 12 Jun 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Business+Wire/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html <p class="bwalignc"> <i>Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030</i> </p><p class="bwalignc"> <i>Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies</i> </p><p class="bwalignc"> <i>Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets</i> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=9bc30e290eb6076fd78c45b399fd2429" shape="rect">CEL-SCI Corporation </a><b>(NYSE American: CVM) </b>today announced it will participate in a formal signing ceremony with Saudi Amarox ("<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsaudiamarox.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=Amarox&amp;index=2&amp;md5=71f13611ea7c0e8f95d5b86a9c320a8e" shape="rect">Amarox</a>") during the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconvention.bio.org%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=BIO+International+Convention&amp;index=3&amp;md5=c6c8b957173e61a9a05dae92bd9e3b86" shape="rect">BIO International Convention</a> 2026 in San Diego, California. The ceremony will mark an important http://www.streetinsider.com/Business+Wire/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html Fri, 12 Jun 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Business+Wire/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html <p class="bwalignc"> <i>Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030</i> </p><p class="bwalignc"> <i>Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies</i> </p><p class="bwalignc"> <i>Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets</i> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=9bc30e290eb6076fd78c45b399fd2429" shape="rect">CEL-SCI Corporation </a><b>(NYSE American: CVM) </b>today announced it will participate in a formal signing ceremony with Saudi Amarox ("<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsaudiamarox.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=Amarox&amp;index=2&amp;md5=71f13611ea7c0e8f95d5b86a9c320a8e" shape="rect">Amarox</a>") during the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconvention.bio.org%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=BIO+International+Convention&amp;index=3&amp;md5=c6c8b957173e61a9a05dae92bd9e3b86" shape="rect">BIO International Convention</a> 2026 in San Diego, California. The ceremony will mark an important http://www.streetinsider.com/Business+Wire/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html Fri, 12 Jun 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Business+Wire/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html <p class="bwalignc"> <i>Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030</i> </p><p class="bwalignc"> <i>Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies</i> </p><p class="bwalignc"> <i>Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets</i> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=9bc30e290eb6076fd78c45b399fd2429" shape="rect">CEL-SCI Corporation </a><b>(NYSE American: CVM) </b>today announced it will participate in a formal signing ceremony with Saudi Amarox ("<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsaudiamarox.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=Amarox&amp;index=2&amp;md5=71f13611ea7c0e8f95d5b86a9c320a8e" shape="rect">Amarox</a>") during the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconvention.bio.org%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=BIO+International+Convention&amp;index=3&amp;md5=c6c8b957173e61a9a05dae92bd9e3b86" shape="rect">BIO International Convention</a> 2026 in San Diego, California. The ceremony will mark an important http://www.streetinsider.com/Business+Wire/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html Fri, 12 Jun 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Business+Wire/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html <p class="bwalignc"> <i>Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030</i> </p><p class="bwalignc"> <i>Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing &amp; Opening Ceremonies</i> </p><p class="bwalignc"> <i>Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets</i> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=9bc30e290eb6076fd78c45b399fd2429" shape="rect">CEL-SCI Corporation </a><b>(NYSE American: CVM) </b>today announced it will participate in a formal signing ceremony with Saudi Amarox ("<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsaudiamarox.com%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=Amarox&amp;index=2&amp;md5=71f13611ea7c0e8f95d5b86a9c320a8e" shape="rect">Amarox</a>") during the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconvention.bio.org%2F&amp;esheet=54552137&amp;newsitemid=20260612660219&amp;lan=en-US&amp;anchor=BIO+International+Convention&amp;index=3&amp;md5=c6c8b957173e61a9a05dae92bd9e3b86" shape="rect">BIO International Convention</a> 2026 in San Diego, California. The ceremony will mark an important http://www.streetinsider.com/Business+Wire/CEL-SCI+and+Saudi+Amarox+to+Conduct+Signing+Ceremony+at+BIO+2026+for+Strategic+Agreement+to+Advance+Commercialization+and+Distribution+of+Multikine%C2%AE+in+Saudi+Arabia/26638355.html Fri, 12 Jun 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++CEL+SCI+CORP+++++++++++++++++++++++++/26558881.html si-local-file:///var/storage/secattach/20260527/26558881.html http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++CEL+SCI+CORP+++++++++++++++++++++++++/26558881.html Wed, 27 May 2026 17:00:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++CEL+SCI+CORP+++++++++++++++++++++++++/26558881.html si-local-file:///var/storage/secattach/20260527/26558881.html http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++CEL+SCI+CORP+++++++++++++++++++++++++/26558881.html Wed, 27 May 2026 17:00:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++CEL+SCI+CORP+++++++++++++++++++++++++/26516545.html si-local-file:///var/storage/secattach/20260519/26516545.html http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++CEL+SCI+CORP+++++++++++++++++++++++++/26516545.html Tue, 19 May 2026 06:02:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++CEL+SCI+CORP+++++++++++++++++++++++++/26516545.html si-local-file:///var/storage/secattach/20260519/26516545.html http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++CEL+SCI+CORP+++++++++++++++++++++++++/26516545.html Tue, 19 May 2026 06:02:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+May+14++Filed+by%3A+KERSTEN+GEERT+R/26510563.html si-local-file:///var/storage/secattach/20260518/26510563.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+May+14++Filed+by%3A+KERSTEN+GEERT+R/26510563.html Mon, 18 May 2026 08:03:00 -0400 CVM O.02168038 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+May+14++Filed+by%3A+KERSTEN+GEERT+R/26510563.html si-local-file:///var/storage/secattach/20260518/26510563.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CEL+SCI+CORP++++++++++++++For%3A+May+14++Filed+by%3A+KERSTEN+GEERT+R/26510563.html Mon, 18 May 2026 08:03:00 -0400 CVM O.02168038 http://www.streetinsider.com/Press+Releases/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html <p class="bwalignc"> <b><i>On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026</i></b> </p><p class="bwalignc"> <b><i>Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia</i></b> </p><p class="bwalignc"> <b><i>50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation</i></b> </p><p class="bwalignc"> <b><i>CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months</i></b> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54537330&amp;newsitemid=20260518705813&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=215d1270d188f68896ba095aa8810690" shape="rect">CEL-SCI Corporation</a> <b>(NYSE American: CVM) </b>today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and http://www.streetinsider.com/Press+Releases/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html Mon, 18 May 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Press+Releases/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html <p class="bwalignc"> <b><i>On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026</i></b> </p><p class="bwalignc"> <b><i>Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia</i></b> </p><p class="bwalignc"> <b><i>50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation</i></b> </p><p class="bwalignc"> <b><i>CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months</i></b> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54537330&amp;newsitemid=20260518705813&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=215d1270d188f68896ba095aa8810690" shape="rect">CEL-SCI Corporation</a> <b>(NYSE American: CVM) </b>today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and http://www.streetinsider.com/Press+Releases/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html Mon, 18 May 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Press+Releases/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html <p class="bwalignc"> <b><i>On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026</i></b> </p><p class="bwalignc"> <b><i>Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia</i></b> </p><p class="bwalignc"> <b><i>50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation</i></b> </p><p class="bwalignc"> <b><i>CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months</i></b> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54537330&amp;newsitemid=20260518705813&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=215d1270d188f68896ba095aa8810690" shape="rect">CEL-SCI Corporation</a> <b>(NYSE American: CVM) </b>today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and http://www.streetinsider.com/Press+Releases/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html Mon, 18 May 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Press+Releases/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html <p class="bwalignc"> <b><i>On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026</i></b> </p><p class="bwalignc"> <b><i>Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia</i></b> </p><p class="bwalignc"> <b><i>50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation</i></b> </p><p class="bwalignc"> <b><i>CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months</i></b> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54537330&amp;newsitemid=20260518705813&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=215d1270d188f68896ba095aa8810690" shape="rect">CEL-SCI Corporation</a> <b>(NYSE American: CVM) </b>today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and http://www.streetinsider.com/Press+Releases/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html Mon, 18 May 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Business+Wire/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html <p class="bwalignc"> <b><i>On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026</i></b> </p><p class="bwalignc"> <b><i>Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia</i></b> </p><p class="bwalignc"> <b><i>50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation</i></b> </p><p class="bwalignc"> <b><i>CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months</i></b> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54537330&amp;newsitemid=20260518705813&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=215d1270d188f68896ba095aa8810690" shape="rect">CEL-SCI Corporation</a> <b>(NYSE American: CVM) </b>today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and http://www.streetinsider.com/Business+Wire/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html Mon, 18 May 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Business+Wire/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html <p class="bwalignc"> <b><i>On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026</i></b> </p><p class="bwalignc"> <b><i>Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia</i></b> </p><p class="bwalignc"> <b><i>50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation</i></b> </p><p class="bwalignc"> <b><i>CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months</i></b> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54537330&amp;newsitemid=20260518705813&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=215d1270d188f68896ba095aa8810690" shape="rect">CEL-SCI Corporation</a> <b>(NYSE American: CVM) </b>today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and http://www.streetinsider.com/Business+Wire/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html Mon, 18 May 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187 http://www.streetinsider.com/Business+Wire/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html <p class="bwalignc"> <b><i>On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026</i></b> </p><p class="bwalignc"> <b><i>Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia</i></b> </p><p class="bwalignc"> <b><i>50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation</i></b> </p><p class="bwalignc"> <b><i>CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months</i></b> </p> <p> VIENNA, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54537330&amp;newsitemid=20260518705813&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=215d1270d188f68896ba095aa8810690" shape="rect">CEL-SCI Corporation</a> <b>(NYSE American: CVM) </b>today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and http://www.streetinsider.com/Business+Wire/CEL-SCI+Reports+Fiscal+Second+Quarter+2026+Results/26510386.html Mon, 18 May 2026 08:00:00 -0400 A.29253873 CVM O.02168038 O.36700187